Stay updated on Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial

Sign up to get notified when there's something new on the Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The page’s revision/version indicator was updated from v3.5.2 to v3.5.3, reflecting a maintenance or release update rather than a change to the study information.
    Difference
    0.0%
    Check dated 2026-04-24T06:27:36.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.0%
    Check dated 2026-04-17T02:42:54.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    24 days ago
    Change Detected
    Summary
    Added Small cell lung carcinoma as a condition tag and introduced a Resources section linking Genetic and Rare Diseases Information Center.
    Difference
    0.1%
    Check dated 2026-04-02T15:35:48.000Z thumbnail image
  5. Check
    38 days ago
    Change Detected
    Summary
    Site revision updated from v3.4.3 to v3.5.0.
    Difference
    0.0%
    Check dated 2026-03-19T06:19:35.000Z thumbnail image
  6. Check
    45 days ago
    Change Detected
    Summary
    Revision label updated from v3.4.2 to v3.4.3 on the page; this reflects a backend/UI update and does not modify study data or content.
    Difference
    0.0%
    Check dated 2026-03-12T02:46:29.000Z thumbnail image
  7. Check
    74 days ago
    Change Detected
    Summary
    Revision: v3.4.2 was added to the page, and the funding-status notice and Revision: v3.4.1 were removed.
    Difference
    0.4%
    Check dated 2026-02-11T14:35:58.000Z thumbnail image

Stay in the know with updates to Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial page.